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Abstract
Background: Human papillomaviruses (HPV) are the aetiological agents of certain benign and
malignant tumours of skin and mucosae; the most important of which is cervical cancer. Also, the
incidence of ano-genital warts, HPV-anal cancer and oropharyngeal cancers are rising. To help
ascertain a useful PCR detection protocol for oropharyngeal cancers, we directly compared three
commonly used primer sets in detection of HPV from different clinical samples.
Methods: We compared PGMY09/11, MY09/11 and GP5+/6+ primers sets in PCRs of 34 clinically
diagnosed samples of genital warts, cervical brushings (with associated histological diagnosis) and
vulval biopsies. All negative samples were subsequently tested using the previously reported
PGMY/GP PCR method and amplicons directly sequenced for confirmation and typing. An
optimised PCR protocol was then compared to a line blot assay for detection of HPV in 15
oropharyngeal cancer samples.
Results: PGMY09/11 primers detected HPV presence in more cervical brushing (100%) and genital
wart (92.9%) samples compared to MY09/11 (90% and 64.3%) and GP5+/6+ (80% and 64.3%)
primer sets, respectively. From vulval biopsies, HPV detection rates were: MY09/11 (63.6%), GP5+/
6+ (54.5%) and PGMY09/11 (54.5%). PGMY/GP nested PCR demonstrated that HPV was present,
and direct sequencing confirmed genotypes. This nested PCR protocol showed detection of HPV
in 10/15 (66.7%) of oropharyngeal cancer samples.
Conclusions: PGMY09/11 primers are the preferred primer set among these three for primary
PCR screening with different clinical samples. MY09/11 and GP5+/6+ may be used (particularly for
cervical samples) but demonstrate lower detection rates. A nested PCR approach (i.e. a PGMY-GP
system) may be required to confirm negativity or to detect low levels of HPV, undetectable using
current primary PCR methods, as demonstrated using oropharyngeal cancer samples.
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Background
Strong epidemiological and molecular evidence has dem-
onstrated human papillomavirus (HPV) to be the aetio-
logical agent of both benign (warts, papillomas) and
malignant tumours (subsets of ano-genital and oropha-
ryngeal carcinomas) [1]. It has been estimated that HPV
accounts for over 5% of total annual worldwide cancers
[2]. The persistence of high-oncogenic risk subtypes has
been demonstrated to be a necessary but not sufficient
cause of cervical cancer [3]; the principal cancer of women
in the developing world and second commonest female
cancer worldwide [4,5] (~510,000 cases with 288,000
deaths annually) [6].
More recently, however, strong evidence linking HPV to
the development of approximately 20-50% (depending
on the anatomical site) [7,8] of head and neck cancers has
been accumulating [9-11]. This is an issue of great global
importance as head and neck cancer is the 5th most com-
mon cancer in the world [12,13]. Mortality has not
improved substantially over the last few decades [14], due
to late diagnosis (75% of cases) and/or recurrent primary
malignancies, and remains at 40-50% at 5 years [15,16].
HPV subtypes are frequently classified as high-risk (HR-
HPV) or low-risk (LR-HPV) for the development of cervi-
cal cancer [5,17]. The recent development and introduc-
tion of prophylactic HPV vaccines for cervical cancer has
now provided fresh impetus to the detection of HPV infec-
tion and associated disease in the community, as govern-
ment initiatives to track the efficacy of vaccination
programmes commence. There is a strengthening case for
the general introduction of the vaccines into the commu-
nity for prevention of HPV-associated non-cervical can-
cers [18].
Currently, the most common tests used to detect genital
HPV in cervical samples are the hybridization assay
Hybrid Capture II (HCII, Digene HPV test, QIAGEN Ltd,
UK), and PCR systems with the degenerate primer sets
MY09/11 and GP5+/6+ [19-22]. These target the con-
served HPV L1 region and detect a broad range of sub-
types, subsequent sequencing allowing specific subtype
identification. However, in multiple HPV infections,
sequencing may miss less prevalent subtypes [23]. The
advent of the PGMY09/11 primer set allowed detection of
increased sensitivity and a broader range of HPV types,
especially in multiply infected cervico-lavage samples
[24]. Furthermore, nested PCR with PGMY/GP+ primer
sets was tested in cervical samples and, compared to MY/
GP+, found to provide a wider range of detectability,
greater sensitivity and performed better in characterisa-
tion of multiple infections [25]. Large meta-analyses have
failed to identify an optimal PCR system for HPV detec-
tion on oropharyngeal cancers [7,8].
In this study, we sought to ascertain an efficient protocol
for HPV detection in different types of clinical samples.
We evaluated HPV detection in DNA from three common
types of genital clinical samples; directly comparing geni-
tal warts, CIN (cervical intra-epithelial neoplasia) brush-
ings and VIN (vulval intra-epithelial neoplasia) lesions
using the MY09/11, GP5+/6+ and PGMY09/11 primer
sets in primary PCR and with subsequent comparison
with a nested PCR approach (PGMY-GP) [25]. We then
compared detection of HPV from oropharyngeal cancers
with a commonly used and commercially available line
blot assay (Linear Array™, Roche Diagnostics Ltd, UK)
which discerns 37 different HPV genotypes. The signifi-
cance of our findings on sensitive PCR detection of HPV
from this range of clinical samples, and in particular,
oropharyngeal cancers, is discussed.
Methods
Study samples
Clinical samples were obtained from patients attending
the Departments of Gynaecological Oncology, Dermatol-
ogy, Addenbrooke's Hospital, Cambridge, UK, Depart-
ment of GU/HIV Medicine, St Mary's Hospital, London,
UK and the Bielefeld Academic Teaching Hospital,
Department of Otorhinolaryngology, Bielefeld, Germany.
All patients gave written informed consent and ethical
approval was obtained from local research ethics commit-
tees. All experiments were performed in the Department
of Pathology at the University of Cambridge.
Genital warts were excised as part of treatment, and snap-
frozen until DNA extraction. A Cervex™ brush (Rovers
Medical Devices B.V. Oss, The Netherlands) was used for
cervical sampling, agitated in PreservCyt™ solution
(Hologic UK Ltd.) for fixation and preservation of cells
and stored at 4°C until DNA extraction. A concomitant
biopsy was taken for CIN staging. All samples were proc-
essed blind. VIN was diagnosed histopathologically from
vulval biopsies, with some tissue processed for DNA.
Oropharyngeal cancer samples, acquired from Germany,
were snap-frozen in liquid nitrogen and transported to the
UK on dry ice prior to DNA extraction. All samples were
diagnosed by the resident consultant histopathologist of
the institutions involved.
DNA extraction from samples
Clinical Wart Samples
Total genomic DNA was extracted from frozen tissue sam-
ples using the DNeasy Blood and Tissue kit (QIAGEN Ltd,
UK) as per manufacturer's instructions. DNA was eluted
with purified (deionized double-distilled) H2O and
stored at -20°C until quantification. DNA purity and con-
centration was ascertained by use of a Nanodrop™ 1000
spectrophotometer. Samples had a 260/280 nm absorb-BMC Cancer 2009, 9:440 http://www.biomedcentral.com/1471-2407/9/440
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ance ratio between 1.8-2.0 and were diluted in purified
H2O to ~5 ng/μl prior to PCR.
Cervical intra-epithelial neoplasia (CIN) or vulval intra-epithelial 
neoplasia (VIN) samples
Total genomic DNA was extracted as described previously
[26] and stored at -20°C until quantification. Standard
strict precautions for prevention of contamination and
false positives (for DNA extraction and all PCR proce-
dures) were observed [27].
Oropharyngeal cancer samples
Oropharyngeal samples were disrupted in a Bullet
Blender™ (Next Advance, Averill Park, USA) in 300 μl
digestion mix (10 mM Tris, pH 7.5; 10 mM EDTA; 0.5%
SDS; 200 μg/ml Proteinase K) for 5 minutes and then
incubated o/n at 37°C. Following Proteinase K inactiva-
tion at 56°C for 10 minutes, the lysate was subjected to a
phenol:choloroform extraction (1:1 volume) and the
supernatant precipitated with 1 ml 100% ethanol. The
DNA was then centrifuged (13,000 rpm, 4°C, 20 mins),
the pellet washed with 70% ethanol, air dried and resus-
pended in 200 μl PBS. RNase digestion and total genomic
DNA isolation was then performed using the DNeasy
Blood and Tissue Kit (QIAGEN Ltd, UK), according to the
manufacturer's instructions and eluted quantified and
stored as outlined above.
PCR methods
Single step PCR analysis
A PCR assay using the PGMY09/11 L1 consensus primer
set was performed as described previously [24]. A 1.5%
agarose gel (in TBE) was then used to confirm the pres-
ence/absence of bands specific for both HPV and human
β-globin. Similarly, PCRs using the GP5+/6+ and MY09/
11 primers were performed as previously described
[19,21]. The PCR cycling conditions were as follows;
PGMY09/11 and MY09/11 primer sets: denaturing step of
95°C for 5 min, followed by 40 cycles of 95°C for 1 min,
55°C for 1 min and 72°C for 1 min. This was followed by
a final extension period of 10 min at 72°C. GP5+/GP6+
primer set: denaturing step of 95°C for 5 min, followed by
40 cycles of 95°C for 1 min, 40°C for 2 min and 72°C for
1.5 min. This was followed by a final extension period of
10 min at 72°C. The sequences of the primers used are
shown in Table 1.
Nested PCR and direct cycle sequencing
PCR reactions that were negative following amplification
with the PGMY09/11 L1 consensus primers were sub-
jected to a further 30 rounds of PCR amplification using
the GP5+/GP6+ primer pair as described previously [19].
Positive bands on a gel were excised, the DNA purified
using QiaQuick Gel Extraction columns (QIAGEN Ltd,
UK) and sequenced directly (Geneservice Ltd, UK). The
sequences were then aligned with known HPV types
(NCBI Basic Local Alignment Search Tool).
Sensitivity of the single and nested PCR approaches
Amplification of serial dilutions of HPV6, HPV16 and
HPV18 plasmids demonstrated equal sensitivity of the
MY, GP and PGMY primer sets at 1-10 copies per cell
input (data not shown). We found that the PGMY/GP
nested PCR system was able to perform consistently at a
high level of sensitivity, namely 0.1-1 copy per cell input
(data not shown). This conforms to the requirements of
the World Health Organisation for the proficient detec-
tion of HPV DNA [28].
PGMY-line blot assay/Linear Array HPV genotyping test (LA HPV GT) 
(Roche Diagnostics Ltd., UK)
The procedure was carried out according to the manufac-
turer's instructions and as previously described [26].
Briefly, PCR amplification was carried out with LA HPV
GT primers as provided: Each 100 μl reaction consisted of
50 μl working master mix containing MgCl2, KCl, Ampli-
taq Gold DNA polymerase, uracil-N-glycosilase, deoxynu-
cleotides (dNTPs) and biotinylated PGMY and β-globin
primers together with 50 μl of DNA sample. DNA tem-
plates were titrated to a concentration of 2-4 ng/μl, i.e.
100-200 ng template DNA per reaction. The Applied Bio-
systems Gold-plated 96-Well GeneAmp PCR System 9700
was programmed as follows: 50°C for 2 min, 95°C for 9
min and 40 cycles of 95°C for 30 s, 55°C for 1 min, 72°C
for 1 min and finally, at 72°C for 5 min before holding it
indefinitely at 72°C. The 40 cycles had a ramp rate set at
50%.
Hybridization to the oligonucleotide probe: 100 μl of
denaturing solution (DS) was added to the PCR product.
All washes and hybridization steps were undertaken in a
24-well tray with lid. The denatured amplicons were
hybridized on to the strip containing specific probes for
37 HPV genotypes and β-globin reference lines before
undergoing stringent washes.
Colorimetric determination with a Linear Array Detection
Kit: the colour change reaction was from streptavidin-
horseradish peroxidase mediated precipitation of working
substrate. Positive reactions appeared as blue lines on the
strip. The strips were interpreted using the HPV reference
guide provided.
Statistical methods
The unweighted Kappa statistic was calculated to assess
the inter-assay concordance and agreement for the rates of
HPV positivity in the clinical samples. Kappa values of 0-
0.2 (slight), 0.21-0.4 (fair), 0.41-0.6 (moderate), 0.61-0.8
(substantial) and 0.81-1.0 (almost perfect) indicated theBMC Cancer 2009, 9:440 http://www.biomedcentral.com/1471-2407/9/440
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Table 1: Primers used to detect HPV in clinical samples.
Primer Set Primer name 5'-3' sequence
GP5+/GP6+ GP5+ TTT GTT ACT GTG GTA GAT ACT AC
GP6+ GAA AAA TAA ACT GTA AAT CAT ATT C
MY09/11 MY09 CGT CCM ARR GGA WAC TGA TC
MY11 GCM CAG GGW CAT AAY AAT GG
PGMY09/11 PGMY11-A GCA CAG GGA CAT AAC AAT GG
PGMY11-B GCG CAG GGC CAC AAT AAT GG
PGMY11-C GCA CAG GGA CAT AAT AAT GG
PGMY11-D GCC CAG GGC CAC AAC AAT GG
PGMY11-E GCT CAG GGT TTA AAC AAT GG
PGMY09-F CGT CCC AAA GGA AAC TGA TC
PGMY09-G CGA CCT AAA GGA AAC TGA TC
PGMY09-H CGT CCA AAA GGA AAC TGA TC
PGMY09-I G CCA AGG GGA AAC TGA TC
PGMY09-J CGT CCC AAA GGA TAC TGA TC
PGMY09-K CGT CCA AGG GGA TAC TGA TC
PGMY09-L CGA CCT AAA GGG AAT TGA TC
PGMY09-M CGA CCT AGT GGA AAT TGA TC
PGMY09-N CGA CCA AGG GGA TAT TGA TC
PGMY09-P G CCC AAC GGA AAC TGA TC
PGMY09-Q CGA CCC AAG GGA AAC TGG TC
PGMY09-R CGT CCT AAA GGA AAC TGG TC
HMB01 GCG ACC CAA TGC AAA TTG GT
GH2O GAA GAG CCA AGG ACA GGT AC
PCO4 CAA CTT CAT CCA CGT TCA CC
Primer sets, names and sequences used for the detection of HPV in clinical samples. GP5+/GP6+ and MY09/11 PCRs consist of a single forward and 
reverse primers, whereas the PGMY09/11 set comprises 5 forward (11A-E) and 13 reverse (09F-HMB01) primers and includes GH2O and PCO4 
β-actin internal controls.BMC Cancer 2009, 9:440 http://www.biomedcentral.com/1471-2407/9/440
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level of agreement between the methods used [29]. Statis-
tical analyses were performed with SPSS software.
Results
Head to head PCR amplification results on warts, cervical 
brushings and vulval specimens
MY and GP primers detected HPV in 9/13 wart samples
(69.2%), whilst PGMY primers detected HPV in all warts
(Table 2). For the cervical brush samples, MY primers
detected HPV in 9/10 samples (90.0%), whilst GP primers
detected HPV in 8/10 samples (80.0%). Again, PGMY
primers detected HPV in all CIN samples. All three primer
sets had the lowest detection rates for vulval samples; HPV
presence was determined in 7/11 (63.6%), 6/11 (54.5%)
and 6/11 (54.5%) VINs for MY, GP and PGMY primers
sets, respectively. We therefore performed a nested PCR
with the PGMY amplicons using the GP5+/GP6+ primers,
on all samples demonstrating a negative or inconclusive
PGMY result. Statistical analysis indicated a moderate
agreement when comparing the three PCR methods with
each other in all samples; MY and GP κ = 0.436 (agree-
ment 76.5%), MY and PGMY κ = 0.472 (agreement
82.4%), GP and PGMY κ = 0.530 (agreement 82.4%). The
overall agreement between the three methods for all sam-
ples was 70.6% (24/34).
Nested PGMY/GP PCR detected HPV in all but one sam-
ple (sample V2post), a biopsy obtained after Imiquimod
treatment for VIN 2 disease. We sequenced the nested
amplicons to confirm true HPV genotype amplification,
and compared these results with those obtained by HPV
Linear Array (Roche Diagnostics Ltd, UK) (Table 3). The
results were consistent, but sequencing revealed a subtype
not detected by the Linear Array from sample C5, namely
HPV87. The Linear Array also detected an additional sub-
type compared to direct sequencing in two samples,
HPV52m in C4 and HPV54 in V4post. Linear array of sam-
ple V2post  revealed HPV subtypes 45 and 54, which
remained undetected by nested PCR. Sample V4on was the
only sample where a typing discrepancy was evident.
Direct comparison of primary PGMY screening, Linear 
Array™ and nested PGMY-GP with sequencing on 
oropharyngeal cancers
PGMY PCR screening of oropharyngeal cancer specimens
showed that no samples were initially positive, although
3 samples proved positive when tested with Linear Array™.
Furthermore, 10 specimens proved positive for HPV when
tested with the nested PCR system (PGMY-GP), as con-
firmed by direct sequencing of the amplified DNA (Table
4).
Discussion
There is a need for better and more time-, labour- and
cost-efficient detection of HPV from clinical samples. For
Table 2: PCR results with 3 primer sets on different clinical 
samples.
Patient Sample MY GP5+/GP6+ PGMY
1W 1 - + +
2W 2 + - +
3W 3 + - +
4W 4 + + +
5W 5 + + +
6W 6 - + +
7W 7 + + +
8W 8 - + +
9W 9 + - +
10 W10 - - +
11 W11 + + +
12 W12 + + +
13 W13 + + +
14 C1 + + +
15 C2 + + +
16 C3 + + +
17 C4 + - +
18 C5 - - +
19 C6 + + +
20 C7 + + +
21 C8 + + +
22 C9 + + +
23 C10 + + +
24 V1 + + +
25 V2pre ++ +
V2post -- -
26 V3pre ++ +BMC Cancer 2009, 9:440 http://www.biomedcentral.com/1471-2407/9/440
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many years, the focus has been on detection of HPV from
cervical samples, and the PCR systems most frequently
used worldwide have used the degenerate/consensus
primers MY09/11 and GP5+/6+ [19-22]. More recently,
the non-degenerate PGMY09/11 primers have been devel-
oped, and shown to detect a broader range of subtypes
from cervical samples with better sensitivity [24].
Earlier epidemiological studies predominantly used the
MY and GP primer sets to detect HPV infection in cervical
cancers, but it was only with increased sensitivity assays
such as nested PCRs that cervical cancers worldwide were
found to be 99.7% HPV positive [3]. Munoz et al. used
both sets of degenerate primers in a multi-centre case-con-
trol study detailing the risks of cervical cancer associated
with different HPV subtypes and found a HPV detection
rate of 90.7% [5]. We tested three primer sets on 34
blinded samples from 30 patients, including samples
from warts, cervical brushings and vulval biopsies to give
a range of clinical tissue samples. Genital warts and cervi-
cal brushings from CIN lesions are essentially 100% pos-
itive for HPV ano-genital subtypes and were used as
positive controls. We then directly compared PGMY pri-
mary screening, nested PCR (PGMY-GP), and the Linear
Array™ system on DNA extracted from oropharyngeal can-
cers.
The PGMY primers performed very well compared to the
MY and GP primers, in the detection of HPV from genital
warts. Identification of HPV subtypes in warts is not rou-
tinely undertaken, as the vast majority of warts have been
shown to be caused by just two subtypes, HPV 6 and 11
[30,31]. However, clinically detectable warts may mask
the presence of HR-HPV infection, particularly in immu-
nosuppressed individuals such as transplant patients or
HIV+ patients. These patients commonly harbour multi-
ple HPV subtype infections and may have increased pre-
disposition to malignancy with HR-HPV. For example,
HIV+ men who have sex with men (MSM) have been
found to have a vastly increased rate of anal cancer [32].
Therefore, there is a requirement for increased screening
and identification of HPV at non-cervical sites.
HPV detection rates in vulval biopsy samples were low for
all three primer sets, probably due to low copy number
infection in the samples, or the presence of subtypes not
detected by these primer sets. Also, many samples were
obtained during treatment of patients, decreasing HPV
viral load (per cell) as patients respond (rev. [33]). In
order to reduce the possibility of false negative results, we
therefore employed an ultra-sensitive nested PCR (PGMY-
GP5+/6+) according to the protocol established by Fues-
sel Haws et al. [25]. This confirmed that the vast majority
of the negative results obtained following primary PCR
were due to insufficient sensitivity. However, Fuessel
Haws et al. also reported a significant problem with false
positives, whereby a sequence from human genomic DNA
was commonly amplified. We felt it was important to
sequence the amplicons for confirmation that HPV was
truly present in the sample. All but one sample (V2post)
were HPV positive, thereby these data show that PGMY
PCR may be useful as first-line PCR screening, but is not
sufficiently sensitive to detect HPV in vulval or head and
neck cancer samples. We suggest that nested PCR should
be performed on clinical specimens if the initial PGMY
PCR is negative, if only to confirm HPV negativity.
It is interesting to note that despite treatment and clinical
resolution of the vulval lesions, we were able to detect the
presence of HPV in all of the samples tested. The same
HPV subtype was present in the post-treatment sample
V4post. The continued presence of a HR-HPV subtype in
the lesion means that the clinician and patient may need
to continue monitoring of the site for clinical recurrence,
suggesting the use of PCR detection of HPV to inform cli-
nicians of the need for continued surveillance of the
infected site(s).
When we applied our regime to oropharyngeal cancers,
we found that the nested PCR system was the most sensi-
tive method. The results are consistent with previous work
showing that determination of HPV DNA viral loads from
the oral cavity were better performed with a nested PCR
system [34], though contrast with recent published work
detecting HPV in oral rinses or swabs with the Linear
Array™ system, type-specific PCR primers or consensus
primers [35-39]. Interestingly, the only HPV positive RRP
was taken from a 31 year old patient, the only sample to
be taken within the usual age range for adult onset of the
V3on ++ +
V3post ++ +
27 V4on +- -
V4post -- -
28 V5pre ++ +
29 V6on -- -
V6post -- -
Wart (W), CIN (C) and VIN (V) samples were tested for HPV using 
three different primers sets. The PGMY primers detected HPV in 
more wart and CIN samples than either MY or GP5+/GP6+ PCR 
systems. There were no significant differences between the three sets 
when VIN samples were analysed. VIN samples collected pre-, on- or 
post- Imiquimod treatment are indicated.
Table 2: PCR results with 3 primer sets on different clinical 
samples. (Continued)BMC Cancer 2009, 9:440 http://www.biomedcentral.com/1471-2407/9/440
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disease [40]. The mean ages of patients with HPV positive
HNSCC was 60.6 years, compared to 69.2 years in
patients with HPV-unrelated disease (n = 15, p = 0.1645,
Mann Whitney U-test). This is consistent with data from a
large US study of HPV prevalence in oral SCCs [41], indi-
cating earlier onset of HPV-related malignancies of the
oral cavity and highlighting pathological differences
between HPV-related and HPV-unrelated disease. The Lin-
ear Array™, incorporating an amplification step, was more
sensitive (determined sensitivity for each subtype is pro-
vided in the manufacturer's manual) than a pure PGMY
primary screening. Our work suggests that even with
direct testing of tumour material, the Linear Array™ system
or "normal" PCR with consensus primers may not be suf-
ficiently sensitive to detect HPV DNA present at low copy
number. This may be important as HPV may be present as
a single copy per cell in advanced pre-malignant or malig-
nant lesions, associated with high-risk HPV integration.
Figure 1 illustrates a suggested protocol for the detection
of HPV in a range of clinical samples.
The performance and type-specific sensitivity of the MY,
GP and PGMY PCR systems have been previously com-
pared and reviewed. The GP and MY primer sets amplify a
wide range of HPV types, with the MY system being shown
to detect significantly more infections with multiple types
[42]. Type-specific amplification differences are also evi-
dent between the two systems, probably reflecting the
degenerate primers of the MY PCR and the consensus
primers of the GP PCR. The PGMY system has been dem-
onstrated to have a type-specific increase in amplification
efficiency, when compared to the MY system from which
it is derived [24]. These findings were confirmed in this
study, PGMY detecting HPV in the greatest number of
clinical samples (29/34), followed by MY (25/34) and GP
(23/34) primer sets. The use of a nested PCR, using GP5+/
GP6+ primers to further amplify PCR products generated
by the PGMY09/11 primer set, has been demonstrated to
be both highly sensitive and capable of detecting more
HPV types per sample [25]. Our use of this method to
detect HPV in oropharyngeal tumours improved detec-
tion from 0/15 to 10/15 samples, compared to a single
round of PGMY PCR, demonstrating its potential value in
the analysis of HNSCC samples.
A PCR approach to HPV detection in clinical samples is
less expensive than the use of the Linear Array™ system.
However, the latter enables detection of multiple HPVs
(37 distinct types) whereas sequencing following PCR
detection often reveals only a single subtype [23], depend-
ent on both viral DNA load and primer binding affinity.
Given that HPV-related HNSCC is clinically different from
HPV-unrelated HNSCC, with improved survival and
lower rates of disease recurrence [43], it is anticipated that
the sensitive detection of HPV DNA in such lesions will
inform both prognosis and treatment.
Conclusions
Our results suggest that the older and commonly used
MY09/11 and GP5+/GP6+ primer sets may not be suffi-
cient for primary HPV detection from non-cervical clinical
samples, and that negative results with primary PGMY
PCR screening should be considered for a GP5+/GP6+
nested PCR. However, the detection of HPV alone from
clinical samples does not automatically lead to the con-
clusion that HPV is involved in the causation of the lesion.
Detection of HPV may be due to HPV "bystanders" or con-
tamination of the sample, due to the ubiquity of HPV on
Table 3: Nested PCR with the PGMY-GP system on previously negative or inconclusive results after primary PCR screen.
Sample PGMY-GP nested PCR HPV sequenced Linear Array
C4 + 58 52m, 58
C5 + 87 -
V2post -N D 4 5 ,  5 4
V4on +1 6 5 4
V4post +1 6 1 6 ,  5 4
V6on +8 1 8 1
V6post +1 6 1 6
Samples negative or weakly positive for HPV using any of the three PCR primer sets were re-amplified using a PGMY-GP5+/GP6+ nested approach. 
Positive samples were directly sequenced to determine HPV type and the result compared to Linear Array.BMC Cancer 2009, 9:440 http://www.biomedcentral.com/1471-2407/9/440
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skin and mucosal surfaces in the human population. Evi-
dence that HPV is involved in the pathogenesis of clinical
disease requires the demonstration of transcriptionally
active virus in lesional cells. In particular, the demonstra-
tion of E6 and E7 oncogenic activity is the "gold standard"
by which HPV activity is measured, therefore future HPV
detection methods should be supplemented by E6/E7
detection, for example using quantitative real-time PCR.
Abbreviations
HPV: human papillomavirus; PCR: polymerase chain
reaction; MSM: men who have sex with men; HIV: human
immunodeficiency virus; TBE: Tris/Borate/EDTA; HR:
high risk; LR: low risk; HG: high grade; LG: low grade.
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Table 4: HPV detection and typing of 15 HNSCC and 3 RRP patients.
HPV detection method
Patient Age Diagnosis PGMY 09/11 Linear Array GP5+/GP6+ nest
1 52 SCC - - HPV 6
2 46 SCC - - HPV 6
3 49 SCC - - HPV 16, mixed
4 58 RRP - - -
5 68 SCC - HPV 16 HPV 16
6 31 RRP HPV 11 HPV 11 HPV 11
76 1 S C C - - -
86 8 S C C - - -
9 54 SCC - HPV 16 HPV 6
10 64 SCC - - HPV 6
11 72 SCC - - HPV 16
12 73 SCC - HPV 11 HPV 6
13 87 RRP - - -
14 69 SCC - - -
15 74 SCC - - -
16 50 SCC - - HPV 40
17 78 SCC - - mixed types
18 74 SCC - - -
HPV +ve HNSCC detection 0/15 3/15 10/15
PCR detection, using the PGMY09/11 primer set was unable to detect the presence of HPV in any of the head and neck squamous cell carcinoma 
(SCC) samples (0/15). Improved detection was achieved using the Linear Array assay (3/15) and following a nested PCR of the PGMY reaction with 
the GP5+/GP6+ primer set (10/15). HPV was only detected in 1/3 of recurrent respiratory papillomatosis (RRP) samples, irrespective of the 
method used. Samples were scored as positive if HPV was detected using one or more of the methods employed.BMC Cancer 2009, 9:440 http://www.biomedcentral.com/1471-2407/9/440
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